AbbVie presents ABBV-466 data in Crohn's disease: higher endoscopic remission than either monotherapy
FROM THE WIRE · FINANCE.YAHOO.COM
In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary endpoint. The treatment difference between ABBV-466 and the monotherapy groups further increased…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive Phase 2a data for an AbbVie candidate may support expectations for the company's drug pipeline.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The Phase 2a study shows higher endoscopic remission with ABBV-466 than monotherapies at Week 12.
- 02The treatment difference increases further at Week 24.
- 03Results will be presented as a late-breaker at the 2026 UEG Week Congress.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets